Systolic heart failure

This study tests whether regular video calls with a nurse can help people with heart failure manage their condition better than audio-only calls. About 140 adults with heart failure will be randomly assigned to receive either video or audio calls at 7, 30, 60, 180, and 365 days a…

This study looks at why the heart failure drug LCZ696 (sacubitril/valsartan) can cause a sudden drop in blood pressure when people first start taking it. The researchers think a natural chemical called bradykinin, which the drug prevents from breaking down, might be responsible. …

This early-stage trial is testing a new gene therapy called AB-1002 in people with advanced heart failure (NYHA Class III). The therapy is given as a single infusion directly into the heart's blood vessels, aiming to deliver a gene that may help heart muscle pump more effectively…

This trial tests a new type of pacemaker for people with heart failure who are having coronary bypass surgery. The pacemaker is designed to mimic a natural pattern called respiratory sinus arrhythmia, where the heart rate speeds up when breathing in and slows down when breathing …

This study tests whether giving heart failure patients a one-page checklist of recommended medications helps doctors prescribe them more often. The checklist lists guideline-approved drugs and doses for heart failure with reduced ejection fraction. Researchers will enroll 4000 pa…

This study looks at whether vericiguat, a drug that stimulates a key enzyme, can improve exercise ability and heart pressure during activity in people with chronic heart failure and reduced ejection fraction. Participants take vericiguat alongside their usual heart medications an…

This study tested whether using a heart MRI to find scar tissue can help decide which people with mild-to-moderate heart failure should get a defibrillator (ICD) to prevent sudden cardiac death. About 449 adults with a weakened heart pump (ejection fraction 36-50%) and scar tissu…

This study tests a structured transitional care program for people with heart failure. The program includes discharge education, phone follow-ups, and home care support for three months after leaving the hospital. Researchers want to see if it helps reduce depression, improve con…

This study looked at whether a type of diabetes medicine called SGLT2 inhibitors can help people with severe heart failure who also have a mechanical heart pump (LVAD). Researchers measured changes in heart size, weight, and kidney function over 6 months in 32 adults. The goal wa…

This completed study in 180 heart failure patients compared the effects of taking Entresto alone versus Entresto plus a second drug (empagliflozin) on mitral valve function and heart pumping ability. Participants had heart failure with reduced ejection fraction and some degree of…

This study tested whether using a smartphone app and phone calls to monitor patients after a heart failure hospital stay helps doctors safely increase their medications. 66 adults with chronic heart failure and low ejection fraction were split into two groups: one received usual …

This study tested a mobile app designed to help people with heart failure monitor their blood pressure, weight, and heart rate daily. The app also tracks symptoms and medications, sharing the data with doctors to guide treatment. Researchers wanted to see if using the app leads t…

This study tested a new drug called JTT-861 in 314 adults with chronic heart failure and reduced pumping ability. Participants took either the drug or a placebo once daily for 12 weeks, alongside their usual heart medications. The goal was to see if the drug improves heart functi…

This study tested a new way to help heart failure patients with weak hearts get the right medications. Over 2,400 people with a heart device took part. A nurse used a simple checklist to guide doctors in prescribing better treatments, aiming to reduce hospital visits and improve …

This study tested whether the diabetes drug ertugliflozin can reduce fluid buildup in the skin and tissues of people with heart failure. 28 adults with reduced heart function took the drug or a placebo for one month each. Researchers measured skin water and sodium content to see …

This study tested a new drug called AC01 in 58 adults with heart failure and reduced pumping ability. The goal was to check safety and how the body processes the drug. Participants received either AC01 or a placebo in increasing doses. The study is complete, but results are not y…

This study tested whether taking a probiotic called Lactobacillus plantarum 299v for 12 weeks could improve exercise ability and blood vessel function in people with heart failure. Ten participants took either the probiotic or a placebo. The goal was to see if the probiotic could…

This study tested a new medicine called CDR132L in 294 people who had a recent heart attack and had weak heart pumping (ejection fraction 45% or less). Participants received one of two doses of CDR132L or a placebo, added to standard care, for 6 months. The goal was to see if the…

This study tested whether a drug called Lokelma (SZC) can help people with both chronic kidney disease and heart failure safely reach higher doses of life-saving heart medications (RAAS inhibitors) without dangerous potassium spikes. 112 adults with stable kidney disease and hear…

This study tested a drug called sacubitril-valsartan in 60 adults with heart failure and a weak heart pump. The goal was to see if the drug could lower the chance of major heart problems like heart attack, stroke, or death, and improve how well the heart pumps blood. Participants…

This study looked at whether a drug called sacubitril/valsartan helps African American patients with a certain type of heart failure (reduced ejection fraction). Researchers wanted to see if it lowers the chance of death or hospital visits for heart problems. Over 6,500 African A…

This study tested a single injection of special stem cells (Rexlemestrocel-L) into the heart for people with chronic heart failure. The goal was to see if it could reduce serious heart events like hospitalizations or death. The trial involved 565 adults and compared the stem cell…

This study looked at whether the drug vericiguat can help reverse harmful changes in the heart's shape and function in people with heart failure. Researchers used advanced ultrasound techniques to measure heart size and pumping ability in 40 participants. The goal was to see if v…

This trial tested a device called Barostim neo that stimulates nerves to help control blood pressure in people with advanced heart failure. Over 1,000 participants received either the device or standard medical care. The goal was to see if the device could reduce heart-related de…

This study tested whether a structured discharge education session using the 'teach-back' method—where patients repeat instructions in their own words—could help heart failure patients better understand their condition and self-care routines. The goal was to reduce 30-day hospita…

This study compares two types of ablation (pulsed-field vs cryoballoon) for treating atrial fibrillation in people with heart failure and reduced pumping function. Researchers looked back at 700 patients who had their first ablation to see which method works better and is safer. …

This study tested a small device that delivers gentle electrical currents to the heart in 70 people with severe heart failure. Participants received either the device plus standard medications or medications alone. The main goal was to see if the device improved the heart's pumpi…

This study looked at health records of 1,249 heart failure patients in Portugal to compare two types of medication: sacubitril/valsartan versus older drugs called ACE inhibitors or ARBs. The goal was to see which treatment better prevents heart failure hospitalizations or death f…

This study collected data from 2,400 adults in China with chronic heart failure to see how well the drug vericiguat works compared to standard treatments. Researchers tracked deaths, hospital stays, and side effects over 12 months. The goal is to understand if vericiguat helps co…

This completed Phase 3 trial tested a web application called SmartHF in 225 adults with heart failure and reduced ejection fraction. The app analyzes patient data and gives personalized medication recommendations that patients can share with their doctor. The goal was to see if u…

This study tested whether probenecid, a medicine usually used for gout, can improve heart function and exercise ability in veterans with heart failure. About 99 veterans with a specific type of heart failure took probenecid twice daily for 180 days. Researchers measured changes i…

This pilot study tested a 'polypill' that combines four heart failure medications into one capsule, aiming to make it easier for patients to stick with their treatment. The trial included 35 adults with heart failure and reduced ejection fraction, some of whom also had HIV. Resea…

This study looked at whether the drug vericiguat can help people who have had a heart attack or unstable angina and also have a weak heart (ejection fraction below 45%). The main goal was to see if it lowers the chance of dying from heart problems or being hospitalized for heart …

This large phase 3 trial tested the drug vericiguat in over 6,000 adults with chronic heart failure and a weakened heart pump. Participants took a daily pill or a placebo to see if the drug could lower the chance of dying from heart problems or being hospitalized for heart failur…

This study looked at whether a clinic led by a heart failure nurse could help patients with heart failure get the right medications after getting an implantable defibrillator (ICD) or cardiac resynchronization therapy (CRT). The goal was to see if this approach improved heart fun…

This study tested whether a single daily pill containing three heart failure drugs could help people with reduced ejection fraction, especially those with low income or from minority groups. 212 adults took either the polypill or standard separate medications. The goal was to see…

This Phase 2 trial tested the drug tovinontrine (CRD-750) against a placebo in 557 adults with chronic heart failure and reduced pumping ability. The goal was to see if the drug safely lowers a key heart stress marker called NT-proBNP over 12 weeks. The study is complete, and res…

This study looked at the safest way to start two heart failure drugs (ARNi and SGLT2i) in 62 adults with a weak heart pump. Researchers compared starting both drugs at the same time versus starting one drug first and adding the other later. The goal was to see which method caused…

This study looked at the safety of the drug sacubitril/valsartan in Japanese children with heart failure. Eight children who had already been in a previous trial took the drug to see if any side effects occurred. The goal was to gather more safety information and provide the drug…

This completed phase 4 trial tested whether vericiguat, a drug already approved for heart failure, can improve blood vessel function, reduce inflammation, and enhance quality of life in 26 people with heart failure with reduced ejection fraction. Participants received either veri…

This study tested whether starting the heart failure drug vericiguat at a 5 mg dose (instead of the usual 2.5 mg) is safe and tolerable. 106 adults with chronic heart failure with reduced ejection fraction took the 5 mg tablet daily for about two weeks. The goal was to see if ski…

This completed trial tested whether ozone therapy can help people with heart failure and reduced ejection fraction. Sixty participants received ozone infusions twice a week for two months. Researchers measured coronary flow reserve, exercise capacity, and heart function before an…

This study tested whether a special clinic (GDMT Clinic) helps heart failure patients get the right medications compared to usual care. About 300 adults with heart failure took part over 12 weeks. The clinic aimed to improve medication use, health status, and heart function.

This pilot study tested a device that stimulates the diaphragm in time with the heartbeat to see if it can improve heart function in people with heart failure. 35 participants with reduced ejection fraction received the implant. The study checked for safety and changes in heart s…

This completed study tested whether special alerts in electronic health records and referrals to pharmacists could help doctors prescribe guideline-recommended heart failure medications more often. Over 4,300 patients with heart failure and reduced ejection fraction took part. Th…

This study tested whether a patient's own bone marrow cells, processed and delivered into the heart muscle, could help people with chronic heart failure. 125 participants were randomly assigned to receive either the cell therapy or a sham procedure. The main goal was to see if th…

This completed study looked at whether the diabetes drug empagliflozin (Jardiance) can help repair heart damage in diabetic patients who had a major heart attack. 200 participants took either 10 mg or 25 mg of the drug daily for 6 months. Researchers measured changes in heart siz…

This study looked at data from 500 people in Germany who started taking vericiguat for chronic heart failure with reduced ejection fraction. Researchers wanted to see how well the drug works outside of clinical trials, in routine medical care. They tracked deaths and hospitalizat…

Heart failure is a serious condition with high death and rehospitalization rates. This study tested whether using a blood marker called ST2 to guide treatment could reduce hospital readmissions within one month. Researchers compared standard care with a strategy that adjusts medi…

This study aimed to create better diagnostic tools for a type of heart failure called heart failure with preserved ejection fraction (HFpEF), which is common in older adults but hard to diagnose. Researchers tested a combination of five blood markers in 91 participants to see if …

This study tested whether nebivolol, a beta-blocker heart drug, could prevent heart failure in 51 boys aged 10-15 with Duchenne muscular dystrophy. Participants had normal heart function at the start and were randomly given either nebivolol or a placebo. The trial found that nebi…

This study tests whether a 12-week home-based breathing exercise program (inspiratory muscle training) can improve physical function, fatigue, and quality of life in adults aged 70 and older with advanced heart failure who are receiving palliative care. Participants use a handhel…

This study tested whether wearing a virtual reality headset during heart device implantation (like pacemakers) could reduce patients' anxiety and pain. 111 adults were randomly assigned to use VR or standard care. The goal was to see if distraction through VR lowers stress and di…

This study looked at whether high-intensity interval training (short bursts of hard exercise) is better than moderate continuous exercise for people with heart failure. Researchers measured nerve activity, blood vessel function, and muscle health in 35 participants. The goal was …

This study tested the drug dapagliflozin (a diabetes medicine) in 50 adults with heart failure due to amyloid cardiomyopathy, a rare condition where abnormal proteins stiffen the heart. Researchers measured changes in quality of life, walking distance, and heart stress markers ov…

This early-stage study tested a new drug called XXB750 in 27 adults with stable heart failure and reduced heart pumping ability. The main goal was to see if the drug is safe and tolerable. Participants received either the drug or a placebo, and researchers monitored for side effe…

This study tested a computer alert that pops up in doctors' electronic health records to remind them to prescribe recommended heart failure medications. Over 1,100 patients with a specific type of heart failure (reduced ejection fraction) took part across four health systems. The…

This study uses healthcare claims data from nearly 24,000 people to see if it can reproduce the results of the EMPEROR-Reduced trial, which tested the diabetes drug empagliflozin against sitagliptin in heart failure patients. The goal is not to test a new treatment, but to learn …

This study looks at 500 adults in Romania with heart failure with reduced ejection fraction who are taking Entresto. Researchers will use existing medical records to see if patients are also receiving other recommended medications like beta-blockers and SGLT2 inhibitors. The goal…

This completed study with over 1,000 participants looked at whether patient surveys and interviews can help doctors spot changes in heart failure. Researchers also collected blood samples to explore links between biology and quality of life. The goal was to see if these tools are…

This study used blood and urine samples from 236 Japanese patients with chronic heart failure to see how biomarkers like BNP change during treatment with sacubitril valsartan or enalapril. Researchers looked for links between biomarker changes and improvements in heart failure sy…

This completed study looked at 334 adults with heart failure and reduced pumping ability. Researchers used ultrasound to measure left atrial strain before and after starting sacubitril/valsartan, a drug known to improve survival. The goal was to see if these measurements could pr…

This study looks at how the drug Sacubitril-Valsartan changes heart function in people with heart failure and reduced pumping ability. Researchers used a non-invasive method to measure heart pressure and volume in 117 participants. The goal is to uncover the mechanisms behind the…

This study tested whether artificial intelligence (AI) could predict a person's risk of developing a specific type of heart failure (HFrEF) up to 5 years in the future, using only a standard ECG. Researchers analyzed data from over 286,000 adults in China and the US. The goal was…

This completed study looked at 60 heart failure patients with reduced pumping function and dangerous heart rhythms. Researchers compared metabolic profiles between those with ischemic (blocked arteries) and non-ischemic (other causes) heart disease. By analyzing blood samples, th…

This completed observational study looked at how often heart failure patients in a French nationwide remote monitoring program were prescribed SGLT2 inhibitors between 2021 and 2024. Researchers analyzed data from over 13,600 adults to see how prescription rates changed over time…

This study tested whether heart failure patients learn more from watching videos or reading text about their condition. 130 patients with heart failure took part. They were randomly assigned to video or text modules, then tested on their knowledge. The goal is to find the best wa…

This study looked at how the heart failure drug Entresto (LCZ696) lowers blood pressure and helps the body get rid of salt. 46 stable heart failure patients took part. Researchers measured blood pressure and urine sodium levels to understand the drug's effects.

This study looked at medical records of 4,000 heart failure patients to see if combining routine blood tests (like NT-proBNP) with heart scan results (like fat density around the heart) can better predict who is at risk of dying within a year. The goal is to improve personalized …

This completed study gathered information on 254 Mexican patients with heart failure and reduced ejection fraction. Researchers looked at patient characteristics, treatments, and outcomes in real-world settings. The goal was to understand current medical practices and identify ba…

This study looked at how lactate, a natural substance made by the body, affects heart function in 12 people with chronic heart failure. Researchers gave lactate as an infusion and as a drink, then measured changes in blood flow and heart pressure. The goal was to understand if la…

This study checked how well German hospitals and heart failure clinics follow recommended treatments for people with a certain type of heart failure (HFrEF) after a serious episode. Researchers looked at the care of 899 patients to see if guidelines were being used. The goal was …

This pilot study tested a computer tool that alerts pharmacists when heart failure patients are not taking their medications as directed. Only 3 pharmacists took part, and the goal was to see if the tool was practical and acceptable. Because it was so small, the results are not e…

This completed study in Greece observed 257 adults with heart failure who were prescribed dapagliflozin as part of their routine care. Researchers tracked how long patients stayed on the drug, any changes in their other heart medications, and how their quality of life changed ove…

This study analyzed data from nearly 5,000 Japanese patients with chronic heart failure who started taking vericiguat as part of their regular care. Researchers tracked outcomes like hospital stays and deaths over one year to see how the drug performs in everyday practice. The go…

This study tested whether a 2-week course of a ketone drink could improve how the heart uses energy in 12 people with chronic heart failure. Researchers used PET scans to measure heart fuel consumption and efficiency. The goal was to understand if ketones could be a better energy…